============================================================ TITLE: AI and Women’s Health: Q&A with Jennifer Barrett TYPE: article VERSION: 1 VERSION_ID: 4832a3d0-3a54-48d9-823b-607cb53da54f GENERATED_AT: 2026-07-10T15:16:56.044Z SUMMARY: Explore how AI can transform women’s health engagement from episodic campaigns to enduring partnerships, enhancing support throughout their health journeys. DATE PUBLISHED: June 10, 2026 DATE MODIFIED: July 8, 2026 READING TIME: 10 min WORD COUNT: 1858 KEYWORDS: Q&A with Jennifer Barrett, From Episodes to a Lifetime SOURCE URL: https://insights.wovenhc.com/ai-and-womens-health-qa-with-jennifer-barrett ============================================================ From Episodes to a Lifetime A Q&A on AI and Women’s Health with Jennifer Barrett, MSc Watch video # From Episodes to a Lifetime A Q&A on AI and Women’s Health with Jennifer Barrett, MSc By Jennifer M. Barrett, MSc and Vin KeaneJune 10, 2026 In a recent BioPharma Dive article, “From Episodes to a Lifetime: AI Can Enable Women’s Health Brands to Build a Partnership That Lasts,” Senior Vice President of Client Services Jennifer Barrett explored how pharmaceutical organizations can reimagine women’s health engagement through AI-enabled strategies. This Q&A expands on the themes from that article, focusing on how brands can move from episodic campaigns to lifetime partnerships across the women’s health journey. By Jennifer M. Barrett, MSc and Vin KeaneJune 10, 2026 In a recent BioPharma Dive article, “From Episodes to a Lifetime: AI Can Enable Women’s Health Brands to Build a Partnership That Lasts,” Senior Vice President of Client Services Jennifer Barrett explored how pharmaceutical organizations can reimagine women’s health engagement through AI-enabled strategies. This Q&A expands on the themes from that article, focusing on how brands can move from episodic campaigns to lifetime partnerships across the women’s health journey. How can AI-enabled pharmaceutical brands move from episodic campaigns to longitudinal engagement in women’s health? AI is arriving at exactly the right moment to reshape how pharmaceutical brands support women over time, rather than just at isolated points.  AI’s real power lies in unifying siloed data—clinical, behavioral, educational, and beyond—into a more continuous view of the health journey. Instead of building campaigns around a single condition or acute episode, marketers and Medical Affairs teams can use AI-driven insights to orchestrate contextually relevant engagement across life stages. This shift enables brands to move from repeatedly “reintroducing” themselves to the same woman at each new event to sustaining a coherent, ongoing relationship. When engagement is designed longitudinally, education becomes more coordinated, opportunities for earlier intervention increase, and women are more likely to feel recognized rather than treated as anonymous, first-time participants each time. Many pivotal moments—like pregnancy—are not diseases but life events, which makes it even more important to adopt a mindset that respects context, preferences, and evolving needs. AI is arriving at exactly the right moment to reshape how pharmaceutical brands support women over time, rather than just at isolated points.  AI’s real power lies in unifying siloed data—clinical, behavioral, educational, and beyond—into a more continuous view of the health journey. Instead of building campaigns around a single condition or acute episode, marketers and Medical Affairs teams can use AI-driven insights to orchestrate contextually relevant engagement across life stages. This shift enables brands to move from repeatedly “reintroducing” themselves to the same woman at each new event to sustaining a coherent, ongoing relationship. When engagement is designed longitudinally, education becomes more coordinated, opportunities for earlier intervention increase, and women are more likely to feel recognized rather than treated as anonymous, first-time participants each time. Many pivotal moments—like pregnancy—are not diseases but life events, which makes it even more important to adopt a mindset that respects context, preferences, and evolving needs. What data foundations are required to support a lifecycle approach to women’s health? A true lifecycle strategy depends on stitching together diverse data sources into a coherent, longitudinal framework. Clinical data, real-world evidence, patient support program information, and even advocacy or education touchpoints are critical components that need to be connected. The goal is to ensure that insights do not begin and end with a single brand initiative, but instead contribute to a broader, cumulative understanding of the woman’s journey across conditions, stages of life, and care settings.However, technical integration alone is not enough. Robust governance structures that span Medical Affairs, commercial teams, and patient advocacy functions are critical so that data is used with scientific integrity and clear guardrails. Lifecycle approaches must be grounded in frameworks that define appropriate use, protect privacy, ensure regulatory compliance, and align segmentation and timing with ethical expectations. A true lifecycle strategy depends on stitching together diverse data sources into a coherent, longitudinal framework. Clinical data, real-world evidence, patient support program information, and even advocacy or education touchpoints are critical components that need to be connected. The goal is to ensure that insights do not begin and end with a single brand initiative, but instead contribute to a broader, cumulative understanding of the woman’s journey across conditions, stages of life, and care settings.However, technical integration alone is not enough. Robust governance structures that span Medical Affairs, commercial teams, and patient advocacy functions are critical so that data is used with scientific integrity and clear guardrails. Lifecycle approaches must be grounded in frameworks that define appropriate use, protect privacy, ensure regulatory compliance, and align segmentation and timing with ethical expectations. Why is now a critical moment for pharmaceutical organizations to invest in AI-driven women’s health strategies? Women’s health has long been underrepresented, both in research and in commercial focus. The current moment is an inflection point. Scientific understanding of fertility, female physiology, and sex-specific responses to therapies is expanding, as is awareness that adverse events and outcomes may differ significantly from those observed in male populations. At the same time, increased investment in women’s health is converging with rapid advances in AI and data infrastructure, making it possible to explore more nuanced, personalized approaches at scale. AI adoption across life sciences has moved from experimental to mainstream, prompting more organizations to ask how far they can thoughtfully push these tools. There is a shared accountability to address long-standing gaps in care and engagement, particularly for women who have historically been underserved. Organizations that move early have an opportunity to shape emerging standards for AI-enabled engagement and define what “good” looks like in women’s health. Those that delay risk remaining fragmented, relying on campaign models designed a decade or more ago that no longer align with the expectations of patients, clinicians, or modern care pathways. Women’s health has long been underrepresented, both in research and in commercial focus. The current moment is an inflection point. Scientific understanding of fertility, female physiology, and sex-specific responses to therapies is expanding, as is awareness that adverse events and outcomes may differ significantly from those observed in male populations. At the same time, increased investment in women’s health is converging with rapid advances in AI and data infrastructure, making it possible to explore more nuanced, personalized approaches at scale. AI adoption across life sciences has moved from experimental to mainstream, prompting more organizations to ask how far they can thoughtfully push these tools. There is a shared accountability to address long-standing gaps in care and engagement, particularly for women who have historically been underserved. Organizations that move early have an opportunity to shape emerging standards for AI-enabled engagement and define what “good” looks like in women’s health. Those that delay risk remaining fragmented, relying on campaign models designed a decade or more ago that no longer align with the expectations of patients, clinicians, or modern care pathways. How can AI be applied responsibly in women’s health while maintaining trust and minimizing bias? Responsible AI is inseparable from trust, especially in a domain as sensitive as women’s health. Strong governance models that make AI usage transparent, ensure continuous validation of inputs and outputs, and clarify who is accountable for decisions are important elements. Responsible use includes proactively identifying and mitigating bias in datasets, ensuring diverse representation, and aligning AI-supported insights with robust clinical evidence rather than treating them as autonomous truth. AI should not be the final decision-maker, but more as a thought partner that can help surface patterns, highlight potential risks, and accelerate synthesis of complex information. Human expertise remains essential, particularly in interpreting outputs, refining prompts, and deciding how to translate insights into real-world actions. In women’s health, where histories of exclusion and bias are well-documented, keeping a “human in the loop” is critical to building and sustaining trust with both patients and health care professionals. Responsible AI is inseparable from trust, especially in a domain as sensitive as women’s health. Strong governance models that make AI usage transparent, ensure continuous validation of inputs and outputs, and clarify who is accountable for decisions are important elements. Responsible use includes proactively identifying and mitigating bias in datasets, ensuring diverse representation, and aligning AI-supported insights with robust clinical evidence rather than treating them as autonomous truth. AI should not be the final decision-maker, but more as a thought partner that can help surface patterns, highlight potential risks, and accelerate synthesis of complex information. Human expertise remains essential, particularly in interpreting outputs, refining prompts, and deciding how to translate insights into real-world actions. In women’s health, where histories of exclusion and bias are well-documented, keeping a “human in the loop” is critical to building and sustaining trust with both patients and health care professionals. What organizational changes are needed to support a lifetime partnership model in women’s health? Shifting from episodic campaigns to lifetime partnerships is as much an organizational evolution as it is a technological one. Many teams are still working through growing pains in defining who they want to be in the age of AI and how they will adapt structures, roles, and processes accordingly. In women’s health, this evolution requires stronger alignment among Medical Affairs, R&D, commercial teams, thought leaders, and compliance partners so that engagement strategies remain both innovative and evidence-based. Organizations must move toward KPIs that prioritize long-term outcomes—such as sustained engagement, improved adherence, or better clinical results—rather than focusing solely on short-term campaign metrics. Ultimately, all of these changes should serve patients first. A lifetime partnership model in women’s health is only meaningful if it remains grounded in patient-centricity, honoring the real journeys women take across their lives and ensuring that AI is used to enhance, not replace, the human care and connection they deserve. Shifting from episodic campaigns to lifetime partnerships is as much an organizational evolution as it is a technological one. Many teams are still working through growing pains in defining who they want to be in the age of AI and how they will adapt structures, roles, and processes accordingly. In women’s health, this evolution requires stronger alignment among Medical Affairs, R&D, commercial teams, thought leaders, and compliance partners so that engagement strategies remain both innovative and evidence-based. Organizations must move toward KPIs that prioritize long-term outcomes—such as sustained engagement, improved adherence, or better clinical results—rather than focusing solely on short-term campaign metrics. Ultimately, all of these changes should serve patients first. A lifetime partnership model in women’s health is only meaningful if it remains grounded in patient-centricity, honoring the real journeys women take across their lives and ensuring that AI is used to enhance, not replace, the human care and connection they deserve. ------------------------------------------------------------ ABOUT THIS CONTENT ------------------------------------------------------------ Source: https://insights.wovenhc.com/ai-and-womens-health-qa-with-jennifer-barrett Published: June 10, 2026 This content is provided for informational purposes. Please visit the original source for the most up-to-date information.